Infectious respiratory diseases are generally caused by the spread of bacteria, viruses, or other pathogenic microbes through saliva & mucus when a person talks, sneezes, coughs, or even laughs, which can severely infect the respiratory system of an individual. With the growing cases of such diseases worldwide, especially among the elderly population, early & accurate diagnosis of the disease-causing pathogens is becoming increasingly crucial for administering appropriate therapies, initiating effective infection control measures, and minimizing the length of hospital stay. As a result, significant R&D investments are being directed toward introducing novel diagnostics & therapeutics to treat patients with infectious respiratory diseases.
The Global Infectious Respiratory Disease Diagnostics Market is expected to grow at a considerable CAGR during the forecast period, i.e., 2023-28. Respiratory infectious diseases like pneumonia, bronchitis, sinus infections, and laryngitis, among others, are the third leading cause of death and result in over 3 million deaths every year globally, cites WHO. The mounting prevalence of these illnesses owing to changing lifestyles, increasing adoption of advanced molecular therapeutics, rapidly rising elderly population, and various initiatives taken by governments & non-profit organizations across different countries worldwide toward minimizing the incidence of these diseases are the prime aspects projected to drive the Infectious Respiratory Disease Diagnostics Market through 2028.
|Study Period||Historical Data: 2018-21|
|Base Year: 2022|
|Forecast Period: 2023-28|
|Regions Covered||North America: USA, Canada, Mexico|
|South America: Brazil, Argentina, Rest of South America|
|Europe: The UK, Germany, France, Spain, Italy, Rest of Europe|
|Asia-Pacific: China, India, Japan, South Korea, Australia, Singapore, Rest of Asia-Pacific|
|Middle East & Africa: Saudi Arabia, UAE, South Africa, Rest of Middle East & Africa|
|Key Companies Profiled||Abacus Diagnostica Oy, Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), Biocartis, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Illumina, Inc., QIAGEN N.V., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., PerkinElmer, Inc., Hologic Inc., Novacyt Group, Qiagen, Quidel Corporation, Seegene, Inc., SDI Diagnostics|
|Unit Denominations||USD Million/Billion|
More and more diagnostics kits, assays, tubes, reagents, & other consumables are being utilized increasingly owing to the growing cancer incidence worldwide. Healthcare firms are substantially investing in introducing new products for infectious respiratory disease diagnostics, as well as in the commercialization of multiplex tests for the simultaneous diagnosis of Respiratory Syncytial Virus (RSV), Covid-19, & influenza, as these illnesses have similar symptoms.
As multiplex testing allows for the simultaneous targeting of multiple genes, which helps minimize the time & cost incurred with traditional diagnostics, such as PCR, the need for its global commercialization is accelerating at a phenomenal pace. Additionally, the launch of new molecular diagnostic tests for SARS-CoV-2 detection, increasing utilization of self-test kits & point-of-care products, as well as rapid technological advancements that have enabled accurate, portable, & cost-effective diagnostics are other crucial aspects projected to stimulate the expansion of the Global Infectious Respiratory Disease Diagnostics Market over the coming years.